We are live on !
Find out more
BB Biotech Portfolio holdings
AUM
$3.98B
Turnover
8.33%
1-Year Est. Return
15.47%
This Fund
S&P 500
This Quarter Est. Return
+15.39%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.55B
AUM Growth
+$396M
(+13%)
Cap. Flow
+$31.1M
Cap. Flow % of AUM
Cap. Flow %
0.88%
Top 10 Holdings %
Top 10 Hldgs %
73.18%
Holding
30
New
2
Increased
6
Reduced
5
Closed
–
Avg Time Held
1.6
years
Top 10 Avg Time Held
1.9
years
Top 20 Avg Time Held
1.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sage Therapeutics
SAGE
|
+$35.1M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$7.62M |
| 3 |
Cidara Therapeutics
CDTX
|
+$7.01M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$3.58M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$3.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
|
+$11.1M |
| 2 |
Puma Biotechnology
PBYI
|
+$7.06M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$5.8M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$5.67M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$2.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.49% |
| 2 | Miscellaneous | 3.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $432M | 12.18% |
3,609,298
+20,000
| +0.6% | +$2.31M |
2013 Q2
10 quarters
|
|
2
Incyte
INCY
$24.1B
| $407M | 11.46% |
3,750,406
| – | – |
2013 Q2
10 quarters
|
|
|
3
Ionis Pharmaceuticals
IONS
$6.45B
| $404M | 11.39% |
6,529,838
-105,000
| -2% | -$5.67M |
2013 Q2
10 quarters
|
|
4
Gilead Sciences
GILD
$208B
| $281M | 7.91% |
2,774,596
| – | – |
2013 Q2
10 quarters
|
|
5
DELISTED
Radius Health, Inc.
RDUS
| $263M | 7.41% |
4,272,140
| – | – |
2014 Q2
6 quarters
|
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
| $197M | 5.56% |
1,034,428
| – | – |
2013 Q2
10 quarters
|
|
|
7
Neurocrine Biosciences
NBIX
$16.2B
| $177M | 4.97% |
3,121,552
-50,000
| -2% | -$2.54M |
2013 Q3
9 quarters
|
|
8
Vertex Pharmaceuticals
VRTX
$138B
| $172M | 4.84% |
1,365,445
| – | – |
2013 Q2
10 quarters
|
|
|
9
Agios Pharmaceuticals
AGIO
$1.69B
| $140M | 3.95% |
2,159,921
+50,000
| +2% | +$3.28M |
2014 Q2
6 quarters
|
|
|
MDVN
10
DELISTED
MEDIVATION, INC.
MDVN
| $125M | 3.51% |
2,581,112
| – | – |
2013 Q2
10 quarters
|
|
11
Halozyme
HALO
$14B
| $122M | 3.43% |
7,029,832
+100,000
| +1% | +$1.59M |
2013 Q2
10 quarters
|
|
12
Regeneron Pharmaceuticals
REGN
$93.4B
| $111M | 3.13% |
205,000
| – | – |
2013 Q3
9 quarters
|
|
13
Alnylam Pharmaceuticals
ALNY
$21B
| $107M | 3% |
1,132,499
| – | – |
2013 Q2
10 quarters
|
|
14
Novavax
NVAX
$1.61B
| $69.9M | 1.97% |
416,500
| – | – |
2014 Q3
5 quarters
|
|
|
TSRO
15
DELISTED
TESARO, Inc.
TSRO
| $64.3M | 1.81% |
1,229,582
+75,000
| +6% | +$3.58M |
2013 Q3
9 quarters
|
|
|
CEMP
16
DELISTED
Cempra, Inc.
CEMP
| $62M | 1.75% |
1,991,900
+100,000
| +5% | +$2.78M |
2014 Q4
4 quarters
|
|
|
JUNO
17
DELISTED
Juno Therapeutics, Inc.
JUNO
| $57.4M | 1.62% |
1,305,000
| – | – |
2015 Q2
2 quarters
|
|
|
ALDR
18
DELISTED
Alder Biopharmaceuticals
ALDR
| $49.9M | 1.41% |
1,510,150
| – | – |
2015 Q2
2 quarters
|
|
|
KITE
19
DELISTED
Kite Pharma, Inc.
KITE
| $46.2M | 1.3% |
750,000
| – | – |
2015 Q2
2 quarters
|
|
20
PTC Therapeutics
PTCT
$5.49B
| $42.2M | 1.19% |
1,302,912
| – | – |
2014 Q4
4 quarters
|
|
|
21
DELISTED
Sage Therapeutics
SAGE
| $41.3M | 1.16% |
+708,663
| New | +$35.1M |
2015 Q4
0 quarters
|
|
|
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $38.2M | 1.08% |
255,719
+45,000
| +21% | +$7.62M |
2015 Q1
3 quarters
|
|
|
23
Puma Biotechnology
PBYI
$504M
| $33.9M | 0.95% |
431,991
-90,000
| -17% | -$7.06M |
2014 Q1
7 quarters
|
|
24
Prothena Corp
PRTA
$405M
| $21.8M | 0.61% |
320,000
| – | – |
2015 Q3
1 quarter
|
|
|
INFI
25
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $21.2M | 0.6% |
2,700,737
| – | – |
2013 Q2
10 quarters
|
|
Similar funds
SA
BB Biotech's Q4 2015 Portfolio in Review
As of Q4 2015, BB Biotech held 30 positions worth $3.55B, up 13% from $3.15B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
BB Biotech's Q4 2015 filing shows 2 new, 6 increased and 5 reduced positions. Its largest new stake was Sage Therapeutics: 708,663 shares worth $41.3M. The largest sale was Tetraphase Pharmaceuticals, Inc., an estimated $11.1M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous.
- BB Biotech's largest Q4 2015 buy was Sage Therapeutics: 708,663 shares worth $41.3M.
- BB Biotech added most to Intercept Pharmaceuticals, Inc. in Q4 2015, an estimated $7.62M increase.
- BB Biotech's biggest Q4 2015 reduction was Tetraphase Pharmaceuticals, Inc., cutting an estimated $11.1M.
- BB Biotech's ten largest holdings make up 73% of its $3.55B portfolio in Q4 2015.
- BB Biotech opened 2 new positions and closed 0 in Q4 2015.
- BB Biotech's portfolio value rose 13% quarter-over-quarter to $3.55B.
Based on BB Biotech's 13F filing for Q4 2015, filed 9 Feb 2016.